It is currently a widely accepted opinion that adaptive. plastic changes in the molecular and cellular components of neuronal signaling systems correlate with the effects on mood and cognition observed after long-term treatment with antidepressant drugs. Protein phosphorylation represents a key step for most signaling systems, and it is involved in the regulation of virtually all cellular functions. Two serine/threonine kinases. Ca2+/calmodulin-dependent protein kinase II and cyclic AMP-dependent protein kinase. have been shown to be activated in the brain following antidepressant treatment. The changes in kinase activity are mirrored by changes in the phosphorylation of selected protein substrates in subcellular compartments (presynaptic terminals and microtubules), which, in rum, ma), contribute to the modulation of synaptic transmission observed with antidepressants. The molecular consequences of protein kinase activation may account for some of the alterations in neural function induced by antidepressants, and may suggest novel possible strategies of pharmacological intervention. (C) 2001 Elsevier Science Inc. All rights reserved.

It is currently a widely accepted opinion that adaptive, plastic changes in the molecular and cellular components of neuronal signaling systems correlate with the effects on mood and cognition observed after long-term treatment with antidepressant drugs. Protein phosphorylation represents a key step for most signaling systems, and it is involved in the regulation of virtually all cellular functions. Two serine/threonine kinases, Ca2+/calmodulin-dependent protein kinase II and cyclic AMP-dependent protein kinase, have been shown to be activated in the brain following antidepressant treatment. The changes in kinase activity are mirrored by changes in the phosphorylation of selected protein substrates in subcellular compartments (presynaptic terminals and microtubules), which, in turn, may contribute to the modulation of synaptic transmission observed with antidepressants. The molecular consequences of protein kinase activation may account for some of the alterations in neural function induced by antidepressants, and may suggest novel possible strategies of pharmacological intervention. © 2001 Elsevier Science Inc.

Serine/threonine kinases as molecular targets of antidepressants: Implications for pharmacological treatment and pathophysiology of affective disorders / Popoli, M.; Mori, S.; Brunello, N.; Perez, J.; Gennarelli, M.; Racagni, G.. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 89:2(2001), pp. 149-170. [10.1016/S0163-7258(00)00108-X]

Serine/threonine kinases as molecular targets of antidepressants: Implications for pharmacological treatment and pathophysiology of affective disorders

Brunello N.;
2001

Abstract

It is currently a widely accepted opinion that adaptive, plastic changes in the molecular and cellular components of neuronal signaling systems correlate with the effects on mood and cognition observed after long-term treatment with antidepressant drugs. Protein phosphorylation represents a key step for most signaling systems, and it is involved in the regulation of virtually all cellular functions. Two serine/threonine kinases, Ca2+/calmodulin-dependent protein kinase II and cyclic AMP-dependent protein kinase, have been shown to be activated in the brain following antidepressant treatment. The changes in kinase activity are mirrored by changes in the phosphorylation of selected protein substrates in subcellular compartments (presynaptic terminals and microtubules), which, in turn, may contribute to the modulation of synaptic transmission observed with antidepressants. The molecular consequences of protein kinase activation may account for some of the alterations in neural function induced by antidepressants, and may suggest novel possible strategies of pharmacological intervention. © 2001 Elsevier Science Inc.
2001
89
2
149
170
Serine/threonine kinases as molecular targets of antidepressants: Implications for pharmacological treatment and pathophysiology of affective disorders / Popoli, M.; Mori, S.; Brunello, N.; Perez, J.; Gennarelli, M.; Racagni, G.. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 89:2(2001), pp. 149-170. [10.1016/S0163-7258(00)00108-X]
Popoli, M.; Mori, S.; Brunello, N.; Perez, J.; Gennarelli, M.; Racagni, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1247728
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 25
social impact